Mouri Atsuto, Hamamoto Yoichiro, Kameyama Nobuhisa, Ibe Tatsuya, Takeoka Shinjiro, Honma Chie, Fukusumi Munehisa, Kamimura Mitsuhiro
Division of Pulmonary Medicine, Dept. of Internal Medicine, National Hospital Organization Disaster Medical Center.
Gan To Kagaku Ryoho. 2015 Sep;42(9):1091-3.
S-1 is one of the effective chemotherapy regimens for treating non-small cell lung cancer. We report of an elderly patient with non-small cell lung cancer who responded to S-1 monotherapy following gefitinib therapy. An 83-year-old woman was diagnosed with advanced adenocarcinoma of the lungs (cT3N3M1a, Stage IV). Considering her age, monotherapy with vinorelbine was administered as first-line chemotherapy. Despite the completion of four courses, she was diagnosed with progressive disease. Thereafter, after considering her status as a non-smoking woman, gefitinib was introduced as second-line chemotherapy, which resulted in significant tumor size reduction.Tumor regrowth was identified 16 months later, and gefitinib was switched to erlotinib, but the tumor kept increasing in size.S -1 monotherapy was introduced as fourth-line chemotherapy, and the tumor began to decrease in size again. A partial response was obtained after 10 months, without serious adverse effects. Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced non-small cell lung cancer.S -1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective.
S-1是治疗非小细胞肺癌的有效化疗方案之一。我们报告了一名老年非小细胞肺癌患者，在吉非替尼治疗后对S-1单药治疗有反应。一名83岁女性被诊断为晚期肺腺癌（cT3N3M1a，IV期）。考虑到她的年龄，一线化疗采用长春瑞滨单药治疗。尽管完成了四个疗程，但她仍被诊断为疾病进展。此后，在考虑到她为不吸烟女性的情况后，引入吉非替尼作为二线化疗，这导致肿瘤大小显著缩小。16个月后发现肿瘤复发，吉非替尼换为厄洛替尼，但肿瘤仍持续增大。引入S-1单药治疗作为四线化疗，肿瘤又开始缩小。10个月后获得部分缓解，且无严重不良反应。在一名晚期非小细胞肺癌老年患者中，S-1单药治疗后使用吉非替尼使肿瘤大小得到了总共27个月的长期控制。S-1单药治疗可能是吉非替尼治疗无效后挽救治疗的选择之一。
